Home » Stocks » ICCC

ImmuCell Corporation (ICCC)

Stock Price: $10.07 USD 0.08 (0.80%)
Updated Jun 24, 2021 2:45 PM EDT - Market open
Market Cap 79.45M
Revenue (ttm) 14.54M
Net Income (ttm) -1.34M
Shares Out 7.22M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $10.07
Previous Close $9.99
Change ($) 0.08
Change (%) 0.80%
Day's Open 10.12
Day's Range 9.95 - 10.09
Day's Volume 1,377
52-Week Range 4.42 - 13.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PORTLAND, Maine, May 19, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientificall...

1 month ago - GlobeNewsWire

PORTLAND, Maine, May 13, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientificall...

1 month ago - GlobeNewsWire

Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET

1 month ago - GlobeNewsWire

PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...

2 months ago - GlobeNewsWire

PORTLAND, Maine, April 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...

2 months ago - GlobeNewsWire

PORTLAND, Maine , Feb. 22, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifica...

4 months ago - GlobeNewsWire

Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET

4 months ago - GlobeNewsWire

PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...

6 months ago - GlobeNewsWire

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET

7 months ago - GlobeNewsWire

PORTLAND, Maine, Oct. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifical...

8 months ago - GlobeNewsWire

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET

10 months ago - GlobeNewsWire

PORTLAND, Maine, July 07, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...

11 months ago - GlobeNewsWire

PORTLAND, Maine, June 16, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...

1 year ago - GlobeNewsWire

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

PORTLAND, Maine, May 14, 2020 /PRNewswire/ -- ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical products tha...

1 year ago - PRNewsWire

PORTLAND, Maine, May 14, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (the “Company” or “ImmuCell”), a growing animal health company that develops, manufactures and markets scientifica...

1 year ago - GlobeNewsWire

PORTLAND, Maine, April 02, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifi...

1 year ago - GlobeNewsWire

PORTLAND, Maine, March 11, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifi...

1 year ago - GlobeNewsWire

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

PORTLAND, Maine, Feb. 19, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...

1 year ago - GlobeNewsWire

PORTLAND, Maine, Jan. 21, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientific...

1 year ago - GlobeNewsWire

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

PORTLAND, Maine, Sept. 17, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scienti...

1 year ago - GlobeNewsWire

PORTLAND, Maine, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientif...

1 year ago - GlobeNewsWire

Second Submission Anticipated Around Q3 2020

1 year ago - GlobeNewsWire

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ImmuCell Corporation's (ICCC) CEO Michael Brigham on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About ICCC

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 30, 1987
CEO
Michael Brigham
Employees
52
Stock Exchange
NASDAQ
Ticker Symbol
ICCC
Full Company Profile

Financial Performance

In 2020, ImmuCell's revenue was $15.34 million, an increase of 11.80% compared to the previous year's $13.72 million. Losses were -$1.02 million, -21.11% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for ImmuCell stock is "Strong Buy" and the 12-month stock price forecast is 14.00.

Price Target
$14.00
Analyst Consensus: Strong Buy